Figure S1. MAP4K1 proteins are relatively highly expressed in glioblastoma multiforme (GBM) U87 and T98G cell lines and patient-derived GBM cells.

(A) MAP4K1 protein expression was detected in different GBM cell lines (U87, U118, T98G, U251) and primary patient-derived GBM cells (G1, G2, G3) by immunoblotting. The relative levels of MAP4K1 were normalized to that in U87 group. (B, C) Representative figures of immunoblot analysis and statistical results of three shRNA knockdown efficiencies in U87 and T98G cells. (A, B, C) Data are represented as the mean ± SD (n = 3). ns, no significance, **P < 0.01 (one-way ANOVA). (D, E) MAP4K1 was knocked out by the CRISPR/Cas9 system in T98G cells. (D) Schematic of specific gRNAs designed to target exon 3 and exon 13 of the MAP4K1 gene. (E) Immunoblot analysis of MAP4K1 protein expression in MAP4K1 knockout T98G cells (n = 3).

Source data are available for this figure.